読み込み中
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$165.56
−$2.77 · -1.65%
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
終値時点
$165.56
−$2.77 · -1.65%
時間外
$169.17
+$3.61 · +2.18%
10月8日 16:20 ET
日中の時刻はETです。市場データは遅延する場合があります。
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
日中レンジ
現在 $165.56
52週レンジ
現在 $165.56
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
56
適正価値
センチメント
62
強気
リスク
48
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
日中レンジ
現在 $165.56
52週レンジ
現在 $165.56
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 9.82億 USD | 7.39億 USD | 5.64億 USD | 4.5億 USD | 3.74億 USD |
| 売上原価 | 3.49億 USD | 2.9億 USD | 2.27億 USD | 1.56億 USD | 1.23億 USD |
| 粗利益 | 6.33億 USD | 4.49億 USD | 3.37億 USD | 2.93億 USD | 2.51億 USD |
| 研究開発 | 3.64億 USD | 3.48億 USD | 3.67億 USD | 3.74億 USD | 2.63億 USD |
| 販売・一般管理 | 7.06億 USD | 5.45億 USD | 4.51億 USD | 4.64億 USD | 3.99億 USD |
| 営業費用 | 10.7億 USD | 8.93億 USD | 9.02億 USD | 8.38億 USD | 6.62億 USD |
| 受取利息 | 3409.5万 USD | 5369.1万 USD | 3536.5万 USD | 606.9万 USD | 393万 USD |
| 支払利息 | 389.7万 USD | 258.1万 USD | 257.8万 USD | 257.7万 USD | 257.7万 USD |
| 減価償却費と償却費 | 3973.6万 USD | 4238.7万 USD | 4288.1万 USD | 3596.2万 USD | 2227.1万 USD |
| 営業利益 | −4.37億 USD | −4.44億 USD | −5.65億 USD | −5.44億 USD | −4.11億 USD |
| 純利益 | −4.16億 USD | −4.36億 USD | −4.79億 USD | −6.55億 USD | −4.06億 USD |
会社概要が更新されました 2026年10月8日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6.37億0.03%2.3兆 USD0.03%$379.56-0.39%
Vanguard Morningstar Small-Cap ETFVB4.61億0.25%1853億 USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK2.65億0.58%447億 USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF2.45億0.25%954億 USD0.05%$233.13-0.15%
iShares Russell Mid-Cap Growth ETFIWP1.09億0.55%201.36億 USD0.23%$140.9-0.40%
ARK Genomic Revolution ETFARKG9971.85万4.73%15.57億 USD0.75%$49.29-1.70%
iShares Russell Mid-Cap ETFIWR8975.17万0.16%565.66億 USD0.18%$108.87+0.37%
iShares Russell 1000 Growth ETFIWF7148.34万0.05%1315.74億 USD0.18%$127.11-1.28%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell Mid-Cap Growth ETFIWPARK Genomic Revolution ETFARKGiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
